insights_auto
Why is DMN down २.८१%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€ ०.०५९
arrow_downward
-२.८१%(-०.००१७) 1D
नोभेम्बर १८, ०८:०४:५४ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१४.०१ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१४.०१ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
Kitco
·
१७ मिनेट पहिले
S&P 500, Nasdaq open higher as Nvidia forecast eases AI jitters
ChartMill
·
४४ मिनेट पहिले
S&P 500 Gap-Down Movers for Nov. 18 Session
TradingView
·
४१ मिनेट पहिले
S&P 500, Nasdaq find footing as Nvidia treads water
FOREX.com
·
४ घण्टा पहिले
S&P 500 Quietly Shrugs Off the Bitcoin and Silver Selloff
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB